Status:
WITHDRAWN
A Phase 1 Study To Estimate The Effects Of PD 0332334 On Lithium Pharmacokinetics In Healthy Subjects
Lead Sponsor:
Pfizer
Conditions:
Generalized Anxiety Disease
Eligibility:
All Genders
21-55 years
Phase:
PHASE1
Brief Summary
The purpose of this study is to investigate if PD 0332334 affects the pharmacokinetics of lithium by co-administering both drugs to healthy adults.
Detailed Description
Additional Study Purpose Details: To investigate potential drug-drug interaction between PD 0332334 and lithium
Eligibility Criteria
Inclusion
- Healthy males and/or females
- Age from 21 to 55 (inclusive)
- BMI ranges from 18 to 30 kg/m2
Exclusion
- Previous participation in a PD 332334 study
- Pregnant or nursing females
- Hypersensitivity (allergic) to lithium, Neurontin (gabapentin), or Lyrica (pregabalin)
Key Trial Info
Start Date :
May 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00820794
Start Date
May 1 2009
End Date
June 1 2009
Last Update
March 5 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.